Neurological Consequences of COVID-19: The “Silent Wave”

September 22, 2020 - Mebourne, Australia – Is the world prepared a wave of neurological consequences that may be on its way as a result of COVID-19? This question is at the forefront of research underway at the Florey Institute of Neuroscience and Mental Health. A team of neuroscientists and clinicians are examining the potential link between COVID-19 and increased risk of Parkinson’s disease, and measures to get ahead of the curve.

Awareness of COVID-19 in Severe Dementia Patients

September 21, 2020 - Tokyo, Japan – The ongoing coronavirus disease 2019 (COVID-19) pandemic has substantially affected patients with dementia and their caregivers. Owing to the restrictive measures taken worldwide to block the spread of COVID-19 outbreaks (including the declaration of a state of emergency in Japan), patients with dementia and their caregivers have not been able to receive the usual support and care. Therefore, this is expected to lead to adverse effects on the patients and their caregivers, and many investigators have warned about the risks [1–3]. In fact, many scheduled appointments for routine outpatients’ examinations and care services have been canceled and postponed owing to the COVID-19 outbreak.

IOS Press Policy Concerning Coronavirus / COVID-19

July 6, 2020 - Due to the spread of the coronavirus (COVID-19) gradually decreasing, the Dutch government is slowly easing its regulations, effective from July 1, 2020.

How Upregulation of a Single Gene by SARS-CoV-2 Can Result in a Cytokine Storm

June 29, 2020 - Amsterdam NL – The SARS-CoV-19 virus initially has a limited capability to invade, attacking only one intracellular genetic target, the aryl hydrocarbon receptors (AhRs). Yet it leads to widely diverse clinical symptoms, suggesting multiple pathogenic mechanisms. Writing in Restorative Neurology and Neuroscience, investigators describe how excessive activation of AhRs via the IDO1-kynurenine-AhR signaling pathway, which is used by many pathogens to establish infection, leads to “Systemic AhR Activation Syndrome” (SAAS). The authors also hypothesize that therapies targeting downregulation of AhRs and IDO1 genes should decrease severity of infection.

COVID-19 May Compound the Social and Economic Burdens of Parkinson’s Disease

May 12, 2020 - Amsterdam, NL – Parkinson's disease (PD) is expected to reach over 14 million cases worldwide by 2040. As longevity increases, so does the number of persons living with PD. Writing in the Journal of Parkinson's Disease (JPD), scientists discuss several avenues through which the COVID-19 pandemic might contribute to the expected exponential growth of PD in the coming years, compounding the economic and societal impacts of the disease.

Passive Immunization May Slow Down SARS-CoV-2 and Boost Immunity in Patients, Buying Time Until Vaccines Are Developed

May 12, 2020 - Amsterdam, NL – The worldwide COVID-19 pandemic has infected more than 4 million people and killed close to 280,000.1 Finding a vaccine has become a global public health priority. However, creating a viable vaccine might take a long time; scientists estimate a vaccine may be available in between 12 and 18 months. A potential interim solution reported in the International Journal of Risk & Safety in Medicine may be a passive vaccine, or passive immummization (PI), which can provide instant, short-term fortification against infectious agents.

Nutritional Management of Patients with COVID-19 Disease

May 1, 2020 - Ancona, Italy – COVID-19 disease is characterized by serious clinical manifestations which could require urgent hospitalization. Prolonged hospitalization, with catabolism and immobilization, induces a decrease in weight and muscle mass which can result in sarcopenia, a condition that impairs respiratory and cardiac function, worsening the prognosis.

Patients with Parkinson’s Disease Face Unique “Hidden Sorrows” Related to the COVID-19 Pandemic

April 3, 2020 - Amsterdam, NL – While much attention has focused on the potential for severe respiratory complications and unfavorable outcomes from the COVID-19 pandemic among patients with Parkinson’s disease (PD), the impact extends beyond these threats. Social distancing requires flexible adaptation to new circumstances, resilience, and a reduction in physical activities, which may be more difficult for patients with PD.